QuidelOrtho Corporation reported total revenue of $693 million for the first quarter of 2025, a decrease from $711 million in the prior year period, primarily due to lower COVID-19 and Donor Screening revenue. However, excluding these factors, revenue grew 5% as reported and 6% in constant currency.
The company achieved an adjusted diluted EPS of $0.74, significantly higher than the $0.44 reported in the prior year period, and surpassed analyst expectations of $0.58 per share. Adjusted EBITDA for the quarter was $160 million, an increase from $132 million in the prior year, with the adjusted EBITDA margin expanding to 23% from 19%.
QuidelOrtho maintained its full-year 2025 financial guidance, projecting total revenues between $2.60 billion and $2.81 billion, adjusted EBITDA between $575 million and $615 million, and adjusted diluted EPS between $2.07 and $2.57. The strong execution on cost-savings initiatives contributed meaningfully to the improved margins and profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.